Stevanato Group S.p.A. (STVN)

Stevanato Group S.p.A. (NYSE:STVN ) Bank of America Global Healthcare Conference 2025 September 24, 2025 5:45 AM EDT Company Participants Marco Dal Lago - Chief Financial Officer Conference Call Participants Michael Ryskin - BofA Securities, Research Division Presentation Michael Ryskin BofA Securities, Research Division I'm on the Bank of America Life Science Tools and Diagnostics team based out of New York.

Stevanato (STVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Stevanato Group S.p.A. (NYSE:STVN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 7:45 AM EDT Company Participants Franco Stevanato - CEO & Executive Chairman Lisa Miles - Chief Communications & Investor Relations Officer Conference Call Participants Kallum Titchmarsh - Morgan Stanley, Research Division Presentation Kallum Titchmarsh Equity Analyst Great.

Investors with an interest in Medical - Drugs stocks have likely encountered both USANA Health Sciences (USNA) and Stevanato Group (STVN). But which of these two companies is the best option for those looking for undervalued stocks?

Investors looking for stocks in the Medical - Drugs sector might want to consider either USANA Health Sciences (USNA) or Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now?

Stevanato Group (STVN) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.1 per share a year ago.

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2025. Second Quarter 2025 Highlights (comparisons to prior-year period) Revenue increased 8% to €280.0 million, and high-value solutions represented 42% of total revenue. Gross profit margin increased 210.

Stevanato (STVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Investors interested in Medical - Drugs stocks are likely familiar with Merck KGaA (MKKGY) and Stevanato Group (STVN). But which of these two stocks offers value investors a better bang for their buck right now?

Stevanato (STVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it has secured €200 million in financing through agreements with BNL BNP Paribas, Cassa Depositi e Prestiti (CDP), and Banco BPM. These fundings are intended to support the Company's ongoing capital expenditure projects in Cisterna di Latina (Italy) and F.

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the second quarter of 2025 on Tuesday, August 5, 2025, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Tuesday, August 5, 2025, to discuss.

The new facility in the U.S. expects to generate €500 million in annual revenues by 2028. The global drug containment solution market is expected to grow at an 8% CAGR from 2024 to 2030. In this market, Stevanato has a competitive advantage. Stevanato's PP&E has increased by 304.61% between 2018 and Q1 2025, indicating the significant investment that the company has dedicated to expanding its operations.

Investors interested in Medical - Drugs stocks are likely familiar with Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks offers value investors a better bang for their buck right now?

Q1 results exceeded expectations, driven by strong Biopharmaceutical and Diagnostic Solutions growth and margin expansion from scaling new facilities. 2025 guidance was reaffirmed despite FX headwinds and Engineering division weakness. High-value products continue to support a robust profit outlook and with a positive sales guidance, we confirm our buy rating.